Evidence map›Paper›PMID 26377898›Full record

ArticleImmunity2015

Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity.

Sakeen W Kashem, Maureen S Riedl, Chen Yao, Christopher N Honda, Lucy Vulchanova, Daniel H Kaplan

Erratum issued Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04629950 (A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis), which is not on this map. Cited by 257 papers.

0numbers the graph read from it
0cells of the map it votes in
257citing papers in PubMed
25.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04629950 phase2completednot on this mapstarted 2021, after this paper: background citation

A Pilot Study of Rimegepant in Moderate Plaque-type Psoriasis

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2021 to 2024Enrolled41ConditionsPsoriasisArmsRimegepant, Placebo
3 · Its place in the literature

Who cites it

257 citing papers in PubMed, 417 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

197 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sakeen W KashemDepartment of Dermatology, Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA.
Maureen S RiedlDepartment of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
Chen YaoDepartment of Dermatology, Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA.
Christopher N HondaDepartment of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
Lucy VulchanovaDepartment of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
Daniel H KaplanDepartment of Dermatology, Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA. Electronic address: dankaplan@pitt.edu.
University of Minnesota · USUniversity of Minnesota Medical Center · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
IMMUNOLOGY TRAINING PROGRAMT32AI007313 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Carla Rothlin · 1989 to 2026
$5.7M
Regulated Activation of Latent-TGFb Determines Leukocyte Occupancy of the Epidermal NicheR01AR060744 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAPLAN, DANIEL H · 2011 to 2020
$4.0M
Skin Dendritic Cells and Humoral ImmunityR01AR067187 · NIAMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAPLAN, DANIEL H · 2015 to 2019
$1.6M
NCATS NIH HHS UL1 TR000114NCATS NIH HHS UL1TR000114NCI NIH HHS P30 CA077598NIAID NIH HHS T32 AI007313NIAMS NIH HHS AR060744NIAMS NIH HHS AR067187NIAMS NIH HHS R01 AR060744NIAMS NIH HHS R01 AR067187NIGMS NIH HHS T32 GM008244
6 · The paper itself

Abstract

Innate resistance to Candida albicans in mucosal tissues requires the production of interleukin-17A (IL-17A) by tissue-resident cells early during infection, but the mechanism of cytokine production has not been precisely defined. In the skin, we found that dermal γδ T cells were the dominant source of IL-17A during C. albicans infection and were required for pathogen resistance. Induction of IL-17A from dermal γδ T cells and resistance to C. albicans required IL-23 production from CD301b(+) dermal dendritic cells (dDCs). In addition, we found that sensory neurons were directly activated by C. albicans. Ablation of sensory neurons increased susceptibility to C. albicans infection, which could be rescued by exogenous addition of the neuropeptide CGRP. These data define a model in which nociceptive pathways in the skin drive production of IL-23 by CD301b(+) dDCs resulting in IL-17A production from γδ T cells and resistance to cutaneous candidiasis.

Indexed as

AnimalsCandida albicansCandidiasisCells, CulturedDendritic CellsDermisFlow CytometryHost-Pathogen InteractionsImmunityInterleukin-17Interleukin-23Lectins, C-TypeMice, Inbred StrainsMice, KnockoutMice, TransgenicOligonucleotide Array Sequence AnalysisInterleukin-17Interleukin-23Lectins, C-TypeMGL2 protein, mouseReceptors, Antigen, T-Cell, gamma-deltaReceptors, Calcitonin Gene-Related Peptide

Identifiers

PMID26377898
PMCPMC4607048
OpenAlexW1623465125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.